课题基金 / 基金详情

项目摘要

项目成果

Mitchell C. Sanders的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请中提出的研究旨在开发ECI生物技术公司有前途的技术,以改进假体周围关节感染(PJI)的诊断,并减少不必要的抗菌干预。PJI的诊断标准在临床实践中尚未标准化,PJI的症状有时难以与其他非感染性炎症和疼痛原因区分。区分感染和其他原因引起的疼痛/炎症对于选择有效的治疗方法和避免不必要的抗生素使用和/或多阶段手术至关重要。ECI进行的一项初步可行性研究“明确确定”了PJI的两个目标标记物,当对从PJI症状患者收集的临床滑液样本进行筛选时。此应用程序的目的是从基于实验室的目标中转换一个或两个目标
英文摘要
DESCRIPTION (provided by applicant): The research proposed in this application aims to develop ECI Biotech's promising technology toward improved diagnosis of periprosthetic joint infection (PJI), and reduction in the unwarranted antimicrobial intervention. Criteria for PJI diagnosis have not been standardized in clinical practice, and symptoms of PJI are sometimes difficult to distinguish from other non-infectious causes of inflammation and pain. Discrimination between infection and other causes of pain/inflammation is crucial to choosing effective treatment and to avoid unnecessary use of antibiotics and/or multistage surgery. An initial feasibility study performed by ECI "clearly identified" two target markers for PJI, when screened against a cohort of clinical synovial fluid samples, gathered from patients with symptoms of PJI. The aim of this application is to transition one or both of these targets from the laboratory-based assay used for initial screening to a prototype point-of- care (PoC) device for future commercialization. In the first aim, the target markers will be integrated into a lateral flow strp PoC diagnostic device. The prototype device will be optimized to mitigate possible cross- reactivity and interference from synovial fluid, especially fluids from persons with autoimmune disorders that involve the synovial fluid especially (rheumatoid arthritis, etc.) In the second aim the prototype device will be tested against a large cohort of patient samples (200+) gathered and banked at the Mayo Clinic, collected from patients undergoing surgical revision for possible PJI. The infection status of these patients will blinded to ECI researchers during assay performance. Diagnosis using ECI's technology is expected to reach 95% accuracy, a significant improvement over current modes of diagnosis currently in use. PUBLIC HEALTH RELEVANCE: Criteria for diagnosis of periprosthetic joint infection (PJI) are not standardized among clinicians, and depend largely on assessment of patient immune response factors, rather than directly assaying for pathogen markers. Misdiagnosis can lead to either inadequate treatment when infections are missed or unnecessary antimicrobial and surgical interventions for infection diagnosis in a joint where no infection actually exists. ECI Biotech's has "clearly identified" two novel markers for detection of infection, which depend on direct markers of pathogenic microbes. Development of ECI Biotech's laboratory assay for PJI in a point-of-care device for commercialization will improve the rate of correct diagnoses, thereby improving patient care and quality of life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Simple and Inexpensive Diagnostic Tools for Yeast Infections
  • 批准号:
    7482629
  • 项目类别:
  • 资助金额:
    $20.09万
  • 财政年份:
    2008
  • 负责人:
    Mitchell C. Sanders
  • 依托单位:
Diagnostic Tool for the Point-of-Care Detection of Infection in Chronic Wounds
  • 批准号:
    7666928
  • 项目类别:
  • 资助金额:
    $51.15万
  • 财政年份:
    2007
  • 负责人:
    Mitchell C. Sanders
  • 依托单位:
Protein Mediated Protection from Microbial Keratitis
  • 批准号:
    6736542
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    Mitchell C. Sanders
  • 依托单位:
COMMERCIAL POTENTIAL FOR P26 IN VITRO AND IN VIVO
  • 批准号:
    2868071
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    1999
  • 负责人:
    Mitchell C. Sanders
  • 依托单位:
海外基金